SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001599298-22-000015
Filing Date
2022-01-25
Accepted
2022-01-25 17:15:45
Documents
14
Period of Report
2022-01-25
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20220125.htm   iXBRL 8-K 40214
2 EX-99.1 a2022_prx0125xannouncement.htm EX-99.1 13444
6 SUMMIT LOGO image_0a.jpg GRAPHIC 88267
  Complete submission text file 0001599298-22-000015.txt   316510

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20220125.xsd EX-101.SCH 1905
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20220125_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20220125_pre.xml EX-101.PRE 12510
8 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20220125_htm.xml XML 11089
Mailing Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142
Business Address ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 617-514-7149
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 22554757
SIC: 2834 Pharmaceutical Preparations